サマリー

市場分析と洞察。世界と日本のβ-ラクタムとβ-ラクタマーゼ阻害剤市場
当レポートでは、世界と日本のBeta-lactamとBeta-lactamase Inhibitors市場に焦点を当てています。
2020年の世界のBeta-lactam and Beta-lactamase Inhibitors市場規模は23715百万米ドルで、2021-2027年の間に1.93%のCAGRで、2027年末には31774百万米ドルに達すると予想されています。日本では、β-ラクタムおよびβ-ラクタマーゼ阻害剤の市場規模は、2020年の2023百万米ドルから2027年には2804百万米ドルまで、予測期間中に2.44%のCAGRで成長すると予測されています。
世界のβ-ラクタムおよびβ-ラクタマーゼ阻害剤の範囲と市場規模
Beta-lactamおよびBeta-lactamase Inhibitors市場は、地域（国）別、プレイヤー別、タイプ別、アプリケーション別に分類されます。世界のBeta-lactam and Beta-lactamase Inhibitors市場に参加しているプレイヤー、ステークホルダー、その他の参加者は、このレポートを強力なリソースとして利用することで、優位に立つことができるでしょう。セグメント別分析では、2016-2027年の期間におけるタイプ別、アプリケーション別の売上高、収益、予測に焦点を当てています。
日本市場については、2016-2027年のβ-ラクタムおよびβ-ラクタマーゼ阻害剤の市場規模を、プレイヤー別、タイプ別、アプリケーション別に分析しています。主要プレイヤーには、日本で重要な役割を果たしているグローバルプレイヤーとローカルプレイヤーが含まれています。
企業別
ファイザー
ノバルティス（サンド社）
TEVA
メルク
アッヴィ(アラガン)
大日本住友製薬
ヒグマ
オーロビンド・ファーマ
Wockhardt
ルパン・リミテッド
フレゼニウス・カビ
ビー・ブラウン
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
日医工(サージェント)
Antibiotice
タイプ別セグメント
ペニシリン系
セファロスポリン系
カルバペネム系抗生物質
モノバクタム系
用途別セグメント
経口
静脈内投与
地域別
北アメリカ
米国
カナダ
アジアパシフィック
中国
日本
韓国
インド
オーストラリア
インドネシア
タイ
マレーシア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中近東・アフリカ
トルコ
サウジアラビア
UAE

ページTOPに戻る

目次

1 STUDY COVERAGE 1
1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction 1
1.2 Market by Type 2
1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type 2
1.2.2 Penicillins 3
1.2.3 Cephalosporins 6
1.2.4 Carbapenems 9
1.2.5 Monobactams 11
1.3 Market by Application 12
1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Application 12
1.3.2 Oral 13
1.3.3 Intravenous 14
1.4 Study Objectives 14
1.5 Years Considered 15
2 EXECUTIVE SUMMARY 16
2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Estimates and Forecasts 16
2.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue 2016-2027 16
2.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales 2016-2027 17
2.2 Beta-lactam and Beta-lactamase Inhibitors Market Size by Region: 2016 VS 2021 VS 2027 18
2.3 Beta-lactam and Beta-lactamase Inhibitors Historical Market Size by Region (2016-2027) 18
2.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Retrospective Market Scenario in Sales by Region: 2016-2021 18
2.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Retrospective Market Scenario in Revenue by Region: 2016-2021 19
2.4 Beta-lactam and Beta-lactamase Inhibitors Market Estimates and Projections by Region (2022-2027) 20
2.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Region (2022-2027) 20
2.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Region (2022-2027) 21
3 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS COMPETITOR LANDSCAPE BY PLAYERS 23
3.1 Global Top Beta-lactam and Beta-lactamase Inhibitors Manufacturers by Sales 23
3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturer (2016-2021) 23
3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturer (2016-2021) 24
3.2 Global Top Beta-lactam and Beta-lactamase Inhibitors Manufacturers by Revenue 25
3.2.1 Key Beta-lactam and Beta-lactamase Inhibitors Manufacturers Covered: Ranking by Revenue 25
3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturer (2016-2021) 26
3.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturer (2016-2021) 27
3.2.4 Global Beta-lactam and Beta-lactamase Inhibitors Market Concentration Ratio (CR5 and HHI) & (2016-2021) 28
3.2.5 Global Top 10 and Top 5 Companies by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2020 29
3.2.6 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 30
3.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Manufacturer (2016-2021) 31
3.4 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base Distribution, Product Type 32
3.4.1 Beta-lactam and Beta-lactamase Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters 32
3.4.2 Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Type 32
3.4.3 Date of International Manufacturers Enter into Beta-lactam and Beta-lactamase Inhibitors Market 33
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 34
4 BREAKDOWN DATA BY TYPE (2016-2027) 36
4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type (2016-2021) 36
4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2016-2021) 36
4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2016-2021) 37
4.1.3 Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Type (2016-2021) 38
4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type (2022-2027) 39
4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Type (2022-2027) 39
4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Type (2022-2027) 39
4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) Forecast by Type (2022-2027) 40
5 BREAKDOWN DATA BY APPLICATION (2016-2027) 41
5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2016-2021) 41
5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2016-2021) 41
5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2016-2021) 42
5.1.3 Beta-lactam and Beta-lactamase Inhibitors Price by Application (2016-2021) 43
5.2 Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Application (2022-2027) 43
5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Application (2022-2027) 43
5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Application (2022-2027) 44
5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2022-2027) 44
6 JAPAN BY PLAYERS, BY TYPE AND BY APPLICATION 46
6.1 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2016-2027 46
6.1.1 Japan Beta-lactam and Beta-lactamase Inhibitors Sales YoY Growth 2016-2027 46
6.1.2 Japan Beta-lactam and Beta-lactamase Inhibitors Revenue YoY Growth 2016-2027 47
6.1.3 Japan Beta-lactam and Beta-lactamase Inhibitors Market Share in Global Market 2016-2027 48
6.2 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Players (International and Local Players) 48
6.2.1 Japan Top Beta-lactam and Beta-lactamase Inhibitors Players by Sales (2016-2021) 49
6.2.2 Japan Top Beta-lactam and Beta-lactamase Inhibitors Players by Revenue (2016-2021) 50
6.3 Japan Beta-lactam and Beta-lactamase Inhibitors Historic Market Review by Type (2016-2021) 53
6.3.1 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2016-2021) 53
6.3.2 Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2016-2021) 53
6.3.3 Japan Beta-lactam and Beta-lactamase Inhibitors Price by Type (2016-2021) 54
6.4 Japan Beta-lactam and Beta-lactamase Inhibitors Market Estimates and Forecasts by Type (2022-2027) 54
6.4.1 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Type (2022-2027) 54
6.4.2 Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Type (2022-2027) 55
6.4.3 Japan Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Type (2022-2027) 56
6.5 Japan Beta-lactam and Beta-lactamase Inhibitors Historic Market Review by Application (2016-2021) 56
6.5.1 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2016-2021) 56
6.5.2 Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2016-2021) 57
6.5.3 Japan Beta-lactam and Beta-lactamase Inhibitors Price by Application (2016-2021) 57
6.6 Japan Beta-lactam and Beta-lactamase Inhibitors Market Estimates and Forecasts by Application (2022-2027) 58
6.6.1 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Application (2022-2027) 58
6.6.2 Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Application (2022-2027) 58
6.6.3 Japan Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2022-2027) 59
7 NORTH AMERICA 60
7.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2016-2027 60
7.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country 61
7.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) 61
7.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) 62
7.2.3 U.S. 63
7.2.4 Canada 64
8 ASIA-PACIFIC 65
8.1 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2016-2027 65
8.2 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Region 66
8.2.1 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2016-2021) 66
8.2.2 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2016-2021) 67
8.2.3 China 68
8.2.4 Japan 69
8.2.5 South Korea 70
8.2.6 India 71
8.2.7 Australia 72
8.2.8 Indonesia 73
8.2.9 Thailand 74
8.2.10 Malaysia 75
8.2.11 Philippines 76
9 EUROPE 78
9.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2016-2027 78
9.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country 79
9.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) 79
9.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) 80
9.2.3 Germany 81
9.2.4 France 82
9.2.5 U.K. 83
9.2.6 Italy 84
9.2.7 Russia 85
10 LATIN AMERICA 86
10.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2016-2027 86
10.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country 87
10.2.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) 87
10.2.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) 88
10.2.3 Mexico 89
10.2.4 Brazil 90
10.2.5 Argentina 91
11 MIDDLE EAST AND AFRICA 92
11.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2016-2027 92
11.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country 93
11.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) 93
11.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) 94
11.2.3 Turkey 95
11.2.4 Saudi Arabia 96
11.2.5 UAE 97
12 COMPANY PROFILES 98
12.1 Pfizer 98
12.1.1 Pfizer Corporation Information 98
12.1.2 Pfizer Description and Business Overview 98
12.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 99
12.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered 99
12.2 Novartis (Sandoz) 102
12.2.1 Novartis (Sandoz) Corporation Information 102
12.2.2 Novartis (Sandoz) Description and Business Overview 102
12.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 103
12.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered 103
12.3 TEVA 106
12.3.1 TEVA Corporation Information 106
12.3.2 TEVA Description and Business Overview 107
12.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 107
12.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered 107
12.4 Merck 109
12.4.1 Merck Corporation Information 109
12.4.2 Merck Description and Business Overview 109
12.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 110
12.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Products Offered 110
12.5 AbbVie (Allergan) 110
12.5.1 AbbVie (Allergan) Corporation Information 110
12.5.2 AbbVie (Allergan) Description and Business Overview 111
12.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 111
12.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered 111
12.6 Sumitomo Dainippon 112
12.6.1 Sumitomo Dainippon Corporation Information 112
12.6.2 Sumitomo Dainippon Description and Business Overview 112
12.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 113
12.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered 113
12.7 Hikma 113
12.7.1 Hikma Corporation Information 113
12.7.2 Hikma Description and Business Overview 114
12.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 114
12.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered 114
12.8 Aurobindo Pharma 116
12.8.1 Aurobindo Pharma Corporation Information 116
12.8.2 Aurobindo Pharma Description and Business Overview 116
12.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 116
12.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered 117
12.9 Wockhardt 117
12.9.1 Wockhardt Corporation Information 117
12.9.2 Wockhardt Description and Business Overview 118
12.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 118
12.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered 118
12.10 Lupin Limited 118
12.10.1 Lupin Limited Corporation Information 118
12.10.2 Lupin Limited Description and Business Overview 119
12.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 119
12.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered 119
12.11 Fresenius Kabi 122
12.11.1 Fresenius Kabi Corporation Information 122
12.11.2 Fresenius Kabi Description and Business Overview 122
12.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 123
12.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered 123
12.12 B. Braun 124
12.12.1 B. Braun Corporation Information 124
12.12.2 B. Braun Description and Business Overview 124
12.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 124
12.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Products Offered 125
12.13 USantibiotics 125
12.13.1 USantibiotics Corporation Information 125
12.13.2 USantibiotics Description and Business Overview 126
12.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 126
12.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Products Offered 126
12.14 Qilu Pharmaceutical 127
12.14.1 Qilu Pharmaceutical Corporation Information 127
12.14.2 Qilu Pharmaceutical Description and Business Overview 127
12.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 128
12.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Products Offered 128
12.15 ACS Dobfar 128
12.15.1 ACS Dobfar Corporation Information 128
12.15.2 ACS Dobfar Description and Business Overview 129
12.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 129
12.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Products Offered 129
12.16 Nichi-Iko (Sagent) 131
12.16.1 Nichi-Iko (Sagent) Corporation Information 131
12.16.2 Nichi-Iko (Sagent) Description and Business Overview 131
12.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 132
12.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Products Offered 132
12.17 Antibiotice 135
12.17.1 Antibiotice Corporation Information 135
12.17.2 Antibiotice Description and Business Overview 135
12.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021) 136
12.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Products Offered 136
13 MARKET DRIVERS, OPPORTUNITIES, CHALLENGES FACTORS ANALYSIS 138
13.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends 138
13.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers 138
13.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges 139
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS 140
14.1 Value Chain Analysis 140
14.2 Beta-lactam and Beta-lactamase Inhibitors Customers 140
14.3 Sales Channels Analysis 141
14.3.1 Sales Channels 141
14.3.2 Distributors 142
15 RESEARCH FINDINGS AND CONCLUSION 145
16 APPENDIX 146
16.1 Research Methodology 146
16.1.1 Methodology/Research Approach 146
16.1.2 Data Source 149
16.2 Author Details 152
16.3 Disclaimer 152